Search results for "Metas"

showing 10 items of 1693 documents

DNA image cytometry. A prognostic tool in squamous cell carcinoma of the esophagus?

1991

In 45 patients who underwent an esophagus resection due to a squamous cell carcinoma, in addition to the TNM classification and usual morphologic criteria, the paraffin-embedded material underwent deparaffinization, was rehydrated, and was mechanically and enzymatically processed into a single-cell solution. For evaluating the DNA histogram this was analyzed with the help of automatic single-cell cytophotometric study. The method, contrary to that of flow cytometric study, allows for the selective analysis of tumor cells due to the electronically, previously given selection criteria, whereas artifacts, stroma, and infection cells remain excluded from analysis. The multivariate analysis show…

MaleCancer ResearchPathologymedicine.medical_specialtyEsophageal NeoplasmsTumor cellsResectionStromaEsophagus CarcinomamedicineHumansBasal cellEsophagusDNA Image CytometryNeoplasm StagingPloidiesbusiness.industryDNA NeoplasmPrognosisSurvival Analysismedicine.anatomical_structureOncologyLymphatic MetastasisCarcinoma Squamous CellFemaleCytophotometrybusinessMedian survivalCancer
researchProduct

Influence of class M1 glutathione S-transferase (GST Mu) polymorphism on GST M1 gene expression level and tumor size in oral squamous cell carcinoma.

2010

Glutathione S-transferases (GST) are antioxidant enzymes and oxidative stress markers in oral carcinogenesis. They present a system of polymorphic proteins. Some variants are associated with increased sensitivity to toxic compounds, as it is known for the GSTM1-null variant allele. However, the influence of the GSTM1 allele variant genotype on GSTM1-mRNA quantity in oral squamous cell carcinoma (OSCC) and normal mucosa as well as the impact on prognosis remains unclear. The genotype for GSTM1 (mutation vs. wild type) was determined by polymerase chain reaction (PCR) using genomic DNA extracted from peripheral blood from 28 OSCC patients. From the same patients, 28 pairs of OSCC cells and no…

MaleCancer ResearchPathologymedicine.medical_specialtyGenotypemedicine.disease_causeGenotypeGene expressionmedicineCarcinomaBiomarkers TumorHumansAlleleneoplasmsAgedGlutathione TransferaseNeoplasm StagingRegulation of gene expressionPolymorphism Geneticintegumentary systembiologyWild typeMouth Mucosamedicine.diseaseMolecular biologyTumor BurdenGene Expression Regulation NeoplasticGlutathione S-transferaseOncologyLymphatic Metastasisbiology.proteinCarcinoma Squamous CellFemaleMouth NeoplasmsOral SurgeryCarcinogenesisOral oncology
researchProduct

Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer.

2006

Despite many pathophysiological analyses, the process of tumor dissemination of hepatocellular carcinoma (HCC) remains vague. In diverse tumor entities, expression of the chemokine receptor, CCR7, has been linked to tumor dissemination and poor prognosis. Therefore, we evaluated, whether CCR7 exerts similar effects in human HCC. CCR7 expression analysis was performed in vitro on human hepatoma cell lines (Huh7, Hep3B, wt HepG2, p53 dominant negative transfected HepG2). In addition, CCR7 expression was evaluated in 39 patients with hepatocellular cancer and correlated with both, tumor and patients characteristics. Human hepatocellular carcinoma samples and hepatoma cell lines displayed varia…

MaleCancer ResearchPathologymedicine.medical_specialtyReceptors CCR7Carcinoma Hepatocellularchemical and pharmacologic phenomenaC-C chemokine receptor type 7BiologyMetastasisChemokine receptorimmune system diseasesCell Line TumormedicineCarcinomaHumansGenetic Predisposition to DiseaseAgedGenes DominantOncogeneLiver NeoplasmsCancerhemic and immune systemsGeneral MedicineMiddle Agedmedicine.diseasePrognosisdigestive system diseasesGene Expression Regulation NeoplasticLymphatic systemOncologyLiverHepatocellular carcinomaLymphatic MetastasisFemaleReceptors ChemokineOncology reports
researchProduct

Overexpression of cyclin D1 and interaction between p27Kip1 and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell …

2005

We have attempted to identify those subgroups of patients most likely to develop lymph node metastases from squamous cell carcinoma of the lower lip (LLSSC). A total of 97 subjects, who did not undergo elective neck dissection, were recruited into the 60-month disease-free survival study. After univariate analysis, tumour size, histological grading, maximal thickness, perineural invasion and immunoreactivity to cyclin D1 and p27Kip1 proteins proved to be significant factors. Tests of the effect of interaction between p27Kip1 LI and tumour thickness yielded that the impact of tumour thickness on the risk of lymph node metastases was modified by the percentage of p27Kip1 positive cells. Subse…

MaleCancer ResearchPathologymedicine.medical_specialtyp27Kip1medicine.medical_treatmentPerineural invasionCell Cycle ProteinsSettore MED/08 - Anatomia PatologicaMetastasisLymph node metastasiCyclin D1Squamous cell carcinomaBiomarkers TumorCarcinomaHumansMedicineCyclin D1Lymph nodeTumour thickness.AgedAged 80 and overbusiness.industryTumor Suppressor ProteinsNeck dissectionMiddle AgedPrognosismedicine.diseaseImmunohistochemistryLymph node metastasis; Squamous cell carcinoma; Lower lip; Cyclin D1; p27Kip1; Tumour thickness.medicine.anatomical_structureOncologyEpidermoid carcinomaLymphatic MetastasisLip NeoplasmsLower lipCarcinoma Squamous CellRegression AnalysisImmunohistochemistryFemaleOral SurgerybusinessCyclin-Dependent Kinase Inhibitor p27Oral Oncology
researchProduct

Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease

2006

Certain chemokines have been proposed to distinctly contribute to tumor growth, dissemination and local immune escape. Expression of the chemokine receptor CXCR4 has been linked to tumor progression in diverse tumor entities. The aim of this study was to evaluate if the expression of CXCR4 influences progression of human pancreatic cancer. CXCR4 expression of pancreatic cancer was retrospectively assessed by immunohistochemistry in 103 patients with pancreatic cancer. Intensity of CXCR4 expression was correlated with both tumor and patient characteristics. Human pancreatic cancer revealed variable intensities of CXCR4 expression. Strong CXCR4 expression was significantly associated with adv…

MaleCancer ResearchReceptors CXCR4Pancreatic diseaseBlotting WesternBiologyAdenocarcinomaMetastasisPancreatic cancermedicineBiomarkers TumorHumansAgedNeoplasm StagingRetrospective StudiesOncogeneCancerGeneral Medicinemedicine.diseaseImmunohistochemistryPancreatic Neoplasmsmedicine.anatomical_structureOncologyTumor progressionCancer researchCA19-9FemalePancreas
researchProduct

BRAF(V600E) MUTATION AND THE BIOLOGY OF PAPILLARY THYROID CANCER

2008

BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers. We evaluated the relationship between BRAF((V600E)) and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF((V600E)) was investigated in a series of 323 PTCs diagnosed in 2002-2005. The correlation between clinicopathological tumor, host, and environmental characteristics and the presence of BRAF((V600E)) were evaluated by both univariate and multivariate analyses. BRAF((V600E)) was found in 38.6% PTCs, with a 52% frequency in the classical PTCs and 26.4% in the tall cell variant. Univariate analysis indi…

MaleCancer Researchendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.disease_causethyroidPapillary thyroid cancerSettore MED/13 - EndocrinologiaImmunoenzyme TechniquesEndocrinologythyroid cancerskin and connective tissue diseasesSicilyMicrodissectionBRAF(V600E)Univariate analysisMutationGeographyReverse Transcriptase Polymerase Chain ReactionThyroidBRAF V600; Papillary Thyroid CancerMiddle Agedhumanitiesmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyLymphatic MetastasisDisease ProgressionFemaleMicrodissectionProto-Oncogene Proteins B-rafPapillary thyroid cancer BRAF(V600E) thyroid thyroid cancerBRAF V600BiologyThyroid carcinomamedicineCarcinomaHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsneoplasmsDNA PrimersLasersPapillary thyroid cancer BRAFmedicine.diseaseCarcinoma Papillarydigestive system diseasesMutationCancer researchV600EFollow-Up StudiesPapillary Thyroid Cancer
researchProduct

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

2006

Recent studies have highlighted that Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily, may be involved in the regulation of osteoblastic activity and in osteoclast differentiation. Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis. Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy b…

MaleCancer Researchmedicine.medical_specialtyBone diseaseOsteoporosisProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsActivin A; Benign prostatic hypertrophy; Bone metastasis; Breast cancer; Neoplasm; > Osteoporosis; Prostate cancer; Transforming growth factor ¦Â; Tumor markersSensitivity and SpecificityGastroenterologyProstate cancerBreast cancerBreast cancerOsteoclastInternal medicineBiomarkers TumormedicineHumansAgedAged 80 and overHematologyProstate cancerbusiness.industryOsteoporosiProstatic NeoplasmsBone metastasisCancerGeneral MedicineMiddle AgedActivin ATransforming growth factor ¦Âmedicine.diseaseBenign prostatic hypertrophyActivinsmedicine.anatomical_structureEndocrinologyOncologyBone metastasiTumor markersOsteoporosisNeoplasmFemalebusiness
researchProduct

Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic canc…

1996

Two doses of megestrol acetate (MA) have been prospectively compared in a random fashion as treatment for cancer-related anorexia-cachexia syndrome (ACS) in 122 patients with progressive soft tissue sarcoma, colorectal, lung, head and neck and renal cancer resistant to systemic chemotherapy. After 30 days of MA, 55% of patients receiving MA at 160 mg day-1 reported an increase in appetite, 27% of patients no variation and 18% complained of a decrease in appetite. Patients treated with MA at 320 mg day-1 reported an increase in appetite in 68% of cases, a stabilisation in 20% of cases and a decrease in 12%. Although an increase in appetite was more frequently observed in patients receiving M…

MaleCancer Researchmedicine.medical_specialtyCachexiamedia_common.quotation_subjectAppetiteAnorexiaGastroenterologyCachexiachemistry.chemical_compoundWeight lossNeoplasmsInternal medicinemedicineHumansProspective StudiesNeoplasm MetastasisProspective cohort studyAgedmedia_commonDose-Response Relationship DrugPerformance statusbusiness.industryMegestrol AcetateBody WeightAppetiteMegestrolSyndromeMiddle Agedmedicine.diseaseAnorexiaSurgeryOncologychemistryMegestrolMegestrol acetateFemalemedicine.symptombusinessResearch Articlemedicine.drugBritish Journal of Cancer
researchProduct

Serum follistatin in patients with prostate cancer metastatic to the bone

2010

The clinical significance of circulating fol- listatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M?) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy sub- jects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Converse…

MaleCancer Researchmedicine.medical_specialtyFollistatinBone diseaseSettore MED/06 - Oncologia MedicaBone metastasis cancer follistatin prostate cancer transforming growth factor beta tumor markersBone Neoplasmsurologic and male genital diseasesGastroenterologySensitivity and SpecificityProstate cancerInternal medicineMedicineHumansClinical significanceAgedHematologybusiness.industryCancerBone metastasisProstatic NeoplasmsGeneral MedicineHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseActivinsProstate-specific antigenEndocrinologyOncologySettore BIO/14 - Farmacologiabusiness
researchProduct

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.

2000

BACKGROUND The lungs are a frequent site of metastasis in patients with melanoma, and this may cause respiratory problems in the terminal phase of the illness. Inhalation interleukin (IL)-2 therapy to the lung has been piloted and appears to be well tolerated. METHODS Twenty-seven patients were treated with single agent dacarbazine and concurrent high dose inhalation IL-2 36 million IU per day). The patients previously had progressed on chemotherapy, predominately dacarbazine-based regimens. Patients included those with American Joint Committee on Cancer Stage IV melanoma, predominately those with lung metastases, but patients with extrapulmonary metastases also were allowed on the study. R…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDacarbazinemedicine.medical_treatmentAntineoplastic AgentsGastroenterologyMetastasisInternal medicineCause of DeathAdministration InhalationAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntineoplastic Agents AlkylatingMelanomaChemotherapyInhalationbusiness.industryMelanomaRespiratory diseaseRemission InductionCancerReproducibility of ResultsConfounding Factors Epidemiologicmedicine.diseaseRecombinant ProteinsSurgeryDacarbazineTreatment OutcomeOncologyConcomitantDisease ProgressionInterleukin-2FemaleSafetybusinessmedicine.drugFollow-Up StudiesCancer
researchProduct